Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:51:02 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:HCM - HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
HCM - Q0.911.50·16.110.115.18+0.614.235.050527714.75  15.30  14.74519.50  11.50516:10:0403:3015 min RT 2¢

Recent Trades - Last 10 of 277
Time ETExPriceChangeVolume
16:10:04Q15.180.611
16:10:04Q15.180.611
16:10:04Q15.180.611
16:10:04Q15.180.611
16:04:45Q15.180.611
16:04:34Q15.180.611
16:00:15Q15.180.611
16:00:15Q15.180.611
16:00:08Q15.180.611
16:00:08Q15.180.611

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-02-06 03:30U:HCMNews ReleaseHUTCHMED to Announce 2025 Final Results
2026-01-13 23:00U:HCMNews ReleaseHUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
2026-01-06 19:00U:HCMNews ReleaseHUTCHMED Announces Positive Topline Results of Phase III Part of ESLIM-02 Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
2026-01-04 19:00U:HCMNews ReleaseHUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naive Pancreatic Ductal Adenocarcinoma
2025-12-30 05:00U:HCMNews ReleaseHUTCHMED Announces NDA Acceptance in China with Priority Review Status for Savolitinib for the treatment of Gastric Cancer Patients with MET Amplification
2025-12-29 03:36U:HCMNews ReleaseHUTCHMED Announces NDA Acceptance in China with Priority Review Status for Fanregratinib in Second-Line Intrahepatic Cholangiocarcinoma
2025-12-16 19:00U:HCMNews ReleaseHUTCHMED Initiates Global Clinical Development of ATTC Candidate HMPL-A251 in Patients with Solid Tumors
2025-12-07 19:00U:HCMNews ReleaseHUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China
2025-11-26 19:00U:HCMNews ReleaseHUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting
2025-11-04 19:00U:HCMNews ReleaseHUTCHMED Announces Enrollment Completed of SAFFRON Global Phase III Trial of ORPATHYS(TM) and TAGRISSO(TM) Combination for Certain Lung Cancer Patients with MET Overexpression and/or Amplification After Progression on TAGRISSO(TM)
2025-11-02 19:00U:HCMNews ReleaseHUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event
2025-10-22 20:00U:HCMNews ReleaseHUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
2025-10-14 04:30U:HCMNews ReleaseHUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
2025-10-13 00:00U:HCMNews ReleaseHUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress
2025-10-01 20:00U:HCMNews ReleaseHUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025
2025-09-11 20:00U:HCMNews ReleaseSave the Date: HUTCHMED to Present R&D Updates on October 31, 2025
2025-09-04 20:00U:HCMNews ReleaseHUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025
2025-08-24 20:20U:HCMNews ReleaseHUTCHMED Announces Appointment of Acting Chief Executive Officer
2025-08-19 20:00U:HCMNews ReleaseHUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS(TM) and TAGRISSO(TM) Combination as a First-Line Therapy for Certain Lung Cancer Patients in China
2025-08-07 07:00U:HCMNews ReleaseHUTCHMED Reports 2025 Interim Results